The researchers stated, "because of the recent implications of toxin producing fungi with 'Sick-Building-Syndrome', ways of treating contaminated indoor environments, as well as preventing the contamination of indoor environments, has become a major concern. Treating drywall with a fungistatic compound such as Sporicidin before installation of the drywall may be a more effective means of reducing the hazards of indoor microbial contamination than eradication of mold growth after the homes/buildings have been occupied."
Sporicidin, an EPA registered hospital disinfectant, was developed by Sporicidin International of Rockville, Maryland. Dr. Robert Schattner, President of Sporicidin International, also developed Chloraseptic Mouthwash. A copy of the study, which has been submitted for publication, is available on request.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.